



## Haegarda® (C1 Esterase Inhibitor Subcutaneous [Human]) (Subcutaneous)

Document Number: IC-0307

Last Review Date: 10/02/2018

Date of Origin: 08/1/2017

Dates Reviewed: 08/2017, 12/2017, 03/2018, 06/2018, 10/2018

### I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Haegarda 2000 IU SDV kit: 16 kits per 28 days
- Haegarda 3000 IU SDV kit: 8 kits per 28 days

#### B. Max Units (per dose and over time) [Medical Benefit]:

- 5,600 billable units per 28 days

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

#### Prophylaxis to prevent Hereditary Angioedema (HAE) attacks †

- Must be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics; **AND**
- Patient must be at least 12 years of age; **AND**
- Patient has a history of one of the following criteria for long-term HAE prophylaxis:
  - History of two (2) or more severe HAE attacks per month (i.e., airway swelling, debilitating cutaneous or gastrointestinal episodes); **OR**
  - Patient is disabled more than 5 days per month by HAE; **OR**
  - History of at least one laryngeal attacks caused by HAE; **AND**
- Treatment of patient with “on-demand” therapy (i.e., Kalbitor, Firazyr, Ruconest, or Berinert) did not provide satisfactory control or access to “on-demand therapy” is limited; **AND**
- Not used in combination with C1 inhibitor prophylaxis (e.g., Cinryze or Takhzyro); **AND**
- Confirmation the patient is avoiding the following possible triggers for HAE attacks:
  - Estrogen-containing oral contraceptive agents **AND** hormone replacement therapy; **AND**

- Antihypertensive agents containing ACE inhibitors; **AND**
- Patient has one of the following clinical presentations consistent with HAE subtype, which must be confirmed by repeat blood testing:

<b>HAE I (C1-Inhibitor deficiency)</b>
<ul style="list-style-type: none"> <li>• Low C1 inhibitor (C1-INH) antigenic level (C1-INH antigenic level below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C1-INH functional level (C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b> <ul style="list-style-type: none"> <li>○ Patient has a family history of HAE; <b>OR</b></li> <li>○ Onset of HAE symptoms occurred before age 30; <b>OR</b></li> <li>○ Normal C1q level</li> </ul> </li> </ul>
<b>HAE II (C1-Inhibitor dysfunction)</b>
<ul style="list-style-type: none"> <li>• Normal to elevated C1-INH antigenic level; <b>AND</b></li> <li>• Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C1-INH functional level (C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)</li> </ul>
<b>HAE with normal C1INH (formerly known as HAE III)</b>
<ul style="list-style-type: none"> <li>• Prophylaxis for HAE with normal C1-INH is not routinely recommended and will be evaluated on a case by case basis</li> </ul>

† FDA Approved Indication(s)

#### IV. Renewal Criteria

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, thromboembolic events, etc.; **AND**
  - Significant improvement in severity and duration of attacks have been achieved and sustained; **OR**
  - Patient requires dose titration due to an inadequate response to therapy (> 1.0 HAE attack/month, regardless of severity/duration)

#### V. Dosage/Administration

Indication	Dose
Prophylaxis of Hereditary Angioedema (HAE) attacks	60 IU/kg body weight injected subcutaneously twice weekly (every 3 or 4 days)

#### VI. Billing Code/Availability Information

Jcode:

**HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2018, Magellan Rx Management

**MagellanRx**  
 MANAGEMENT<sup>SM</sup>

- J0599 – Injection, c-1 esterase inhibitor (human), (haegarda), 10 units: 1 billable unit = 10 IU (effective 1/1/19)
- J3590 – Unclassified Biologics
- C9015 – Injection, c-1 esterase inhibitor (human), Haegarda, 10 units: 1 billable unit = 10 IU. (inactive 1/1/2019)

NDC:

- Haegarda 2000 IU single-use vial kit: 63833-0828-xx
- Haegarda 3000 IU single-use vial kit: 63833-0829-xx

## VII. References

1. HAEGARDA [package insert]. Kankakee, IL; CSL Behring LLC; October 2017. Accessed August 2018.
2. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. *J Allergy Clin Immunol*. 2004 Sep;114(3):629-37.
3. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. *Eur J Dermatol*. Mar-Apr 2009;19(2):147-151.
4. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. *Allergy Asthma Clin Immunol*. 2010;6(1):24.
5. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. *World Allergy Organ J*. 2012 Dec;5(12):182-99.
6. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. *Clin Exp Immunol*. 2005;139(3):379.
7. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. *Asthma Clin Immunol*. 2014 Oct 24;10(1):50. doi: 10.1186/1710-1492-10-50.
8. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol*. 2013 Jun;131(6):1491-3. doi: 10.1016/j.jaci.2013.03.034.
9. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. *J Allergy Clin Immunol Pract*. 2013 Sep-Oct;1(5):458-67.
10. Longhurst H, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. *N Eng J Med*. 2017;376:1131-1140.
11. Maurer M, Mager M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. *Allergy*. 2018 Jan 10. doi: 10.1111/all.13384.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D84.1	Defects in the complement system

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

### Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC